Novartis to provide ‘no-profit’ generics to low income countries to help combat COVID-19
July 16, 2020Business Services COVID-19, Novartis, coronavirus, hydroxychloroquine
The Sandoz division of Novartis will not make a profit on the 15 generics it is making available to developing …
Trump administration orders hospitals to stop sending COVID-19 data to the CDC
July 16, 2020Business Services CDC, COVID, coronavirus
The Trump administration has ordered hospitals to stop sending coronavirus patient data to the Centers for Disease Control and Prevention …
Gilteritinib becomes first NICE-approved oral therapy for relapsed or refractory acute myeloid leukaemia
July 16, 2020Sales and Marketing Atellas, NICE, UK, acute myeloid leukaemia, gilteritinib
NICE has revealed its recommendation of Astellas’ gilteritinib for routine use as a monotherapy on the NHS in England and …
Jannsen’s Tremfya becomes first FDA-approved IL-23 inhibitor for active psoriatic arthritis
July 15, 2020Research and Development, Sales and Marketing FDA, Jannsen, Tremfya, active psoriatic arthritis
Janssen has reported that its therapy Tremfya (guselkumab) has become the first selective interleukin (IL)-23 inhibitor approved by the FDA …
UK lockdown caused infection ‘R’ rate to drop as low as 0.57, according to a new study
July 15, 2020Research and Development COVID, COVID-19, Lockdown, coronavirus
A new study showed that the coronavirus infection rate hit its lowest point one month before lockdown restrictions were lifted. …
FDA committee backs GSK’s belantamab mafodotin in relapsed or refractory multiple myeloma
July 15, 2020Research and Development, Sales and Marketing Cancer, FDA, GSK, multiple myeloma, pharma
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has moved to recommend the use of GlaxoSmithKline’s belantamab mafodotin, or GSK2857916 as …
Moderna’s COVID-19 vaccine candidate set for final testing in the US
July 15, 2020Research and Development COVID-19, coronavirus
The first COVID-19 vaccine being used in clinical trials in the US is set to begin final testing. The experimental …
Pharmafile.com’s weekly COVID-19 news round-up
July 15, 2020Research and Development COVID-19, coronavirus, vaccines
The coronavirus news this week focuses on therapeutics, with Gilead’s remdesivir reducing the risk of death in 62% of severe …
People in England must wear face mask in shops from 24 July
July 14, 2020Manufacturing and Production coronavirus, masks
Face masks are set to become mandatory in shops across England beginning on 24 July, following months of mixed messaging …
Malaria prophylactic tafenoquine shows antiviral activity against SARS-CoV-2 in cell cultures
July 14, 2020Manufacturing and Production, Research and Development 60 Degrees Pharmaceuticals, COVID-19, coronavirus, pharma
Specialist tropical disease drug firm 60 Degrees Pharmaceuticals has revealed that its therapy Arakoda (tafenoquine) has been shown in cell …
Arthritis drug reduces COVID-19 deaths for patients on ventilators
July 14, 2020Manufacturing and Production COVID-19, coronavirus
The rheumatoid arthritis drug tocilizumab reduces death rates in coronavirus patients on ventilation, according to new studies.
Roche and Blueprint extend collaboration with $1.7 billion cancer drug development and commercialisation deal
July 14, 2020Manufacturing and Production, Research and Development Blueprint Medicines, Cancer, Roche, pralsetinib
Roche and Blueprint Medicines have come together in a $1.7 billion development and commercialisation partnership focused on precision therapy pralsetinib …
Pfizer and BioNTech’s COVID-19 vaccines to have their development fast tracked by the FDA
July 14, 2020Manufacturing and Production, Research and Development COVID-19, Vaccine, coronavirus
The FDA has granted Pfizer and BioNTech’s COVID-19 vaccine candidates Fast Track status to speed up their development and review. …
Itolizumab “significantly reduced mortality” in hospitalised COVID-19 patients with respiratory distress, secures emergency use authorisation in India
July 13, 2020Research and Development, Sales and Marketing COVID-19, Itolizumab, coronavirus
Itolizumab, a drug currently being developed by biotech firm Equillium for autoimmune and inflammatory disorders, “significantly reduced mortality” in hospitalised …
WHO reports record daily increase in global COVID-19 cases
July 13, 2020Sales and Marketing COVID-19, coronavirus
The World Health Organization reported the largest daily increase in COVID-19 cases since the pandemic began. Over the weekend there …
Russia claims it has completed the first human trial for COVID-19 vaccine
July 13, 2020Sales and Marketing COVID-19, coronavirus, vaccines
Russia has become the first country to complete a COVID-19 vaccine trial on humans, according to the Russian News Agency. …
Remdesivir cuts death risk by 62% in coronavirus patients, new study shows
July 13, 2020Sales and Marketing COVID-19, coronavirus
Gilead’s remdesivir reduced the risk of death in 62% of severe COVID-19 patients, according to a new study. The company …
Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer
July 13, 2020Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq
Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …
Dr Edwin Moses appointed as Chairman of the Board of Sensorin
July 10, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Sensorin have appointed Dr Edwin Moses as the Chairman of its Board of Directors Moses joins from his previous role …
New data shows Gilead’s remdesivir “potently inhibited” SARS-CoV-2 in human lung cell cultures
July 10, 2020Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir
New findings published from researchers at Vanderbilt University Medical Center (VUMC) at the University of North Carolina, as well as …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
